| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1007002589 |
| P356 | DOI | 10.1023/A:1006334404767 |
| P698 | PubMed publication ID | 10759404 |
| P2093 | author name string | Nemunaitis J | |
| P2860 | cites work | Active immunotherapy with B.C.G. for recurrent malignant melanoma | Q69997796 |
| Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells. I. Parameters for optimal therapeutic effects | Q70030614 | ||
| Immunotherapy of advanced gynecologic cancer patients utilizing mumps virus | Q70062831 | ||
| Lymphosarcoma | Q71357863 | ||
| Viruses as oncolytic agents: a new age for "therapeutic" viruses? | Q72083108 | ||
| Safety evaluation of Ad5CMV-p53 in vitro and in vivo | Q72202236 | ||
| Serologic response to human melanoma lines from patients with melanoma undergoing treatment with vaccinia melanoma oncolysates | Q72395339 | ||
| Regression of Hodgkin's disease after measles | Q72470432 | ||
| Remissions in leukemia of childhood following acute infectious disease: staphylococcus and streptococcus, varicella, and feline panleukopenia | Q73125018 | ||
| Note on the experimental use of rabies vaccine for melanomatosis | Q75449355 | ||
| Effects of concurrent infections and their toxins on the course of leukemia | Q78456917 | ||
| Multiple myeloma: report of a case showing unusual remission lasting two years following severe hepatitis | Q78718048 | ||
| [A case of prolonged spontaneous remission in a patient with chronic lymphatic leukemia.] | Q79436120 | ||
| Studies in Hodgkin's syndrome; the association of viral hepatitis and Hodgkin's disease; a preliminary report | Q80353957 | ||
| Studies on the propagation in vitro of poliomyelitis viruses. IV. Viral multiplication in a stable strain of human malignant epithelial cells (strain HeLa) derived from an epidermoid carcinoma of the cervix | Q24680744 | ||
| Human papillomavirus E6 proteins bind p53 in vivo and abrogate p53-mediated repression of transcription | Q28187745 | ||
| Low-energy He/Ne laser in the prevention of radiation-induced mucositis. A multicenter phase III randomized study in patients with head and neck cancer | Q30743857 | ||
| Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial | Q32055417 | ||
| Thymidine kinase-negative herpes simplex virus mutants establish latency in mouse trigeminal ganglia but do not reactivate. | Q33864322 | ||
| Analysis of human tonsil and cancer DNAs and RNAs for DNA sequences of group C (serotypes 1, 2, 5, and 6) human adenoviruses | Q33990268 | ||
| Studies on the use of viruses in the treatment of carcinoma of the cervix | Q34240325 | ||
| Attenuated multi–mutated herpes simplex virus–1 for the treatment of malignant gliomas | Q34297434 | ||
| An adenovirus mutant that replicates selectively in p53-deficient human tumor cells | Q34399844 | ||
| Smallpox: gone but not forgotten | Q34477975 | ||
| Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection | Q34562704 | ||
| Vaccinia virus for human gene therapy. | Q45755568 | ||
| In situ cancer vaccination: an IL-12 defective vector/replication-competent herpes simplex virus combination induces local and systemic antitumor activity | Q45756276 | ||
| Preferential cytotoxic effect of Newcastle disease virus on lymphoma cells | Q45769847 | ||
| Selective destruction of gliomas in immunocompetent rats by thymidine kinase-defective herpes simplex virus type 1. | Q45780982 | ||
| The effect of a mesogenic and a lentogenic Newcastle disease virus strain on Burkitt lymphoma Daudi cells | Q45786310 | ||
| Treatment of human malignant meningiomas by G207, a replication-competent multimutated herpes simplex virus 1 | Q45788447 | ||
| Adjuvant treatment of locally advanced renal cancer with autologous virus-modified tumor vaccines | Q45788946 | ||
| A phase II study on the postsurgical management of Stage II malignant melanoma with a Newcastle disease virus oncolysate | Q45793855 | ||
| The augmentation of tumor-specific immunity by virus help. II. Enhanced induction of cytotoxic T lymphocyte and antibody responses to tumor antigens by vaccinia virus-reactive helper T cells | Q45804035 | ||
| Biochemical studies on the herpes simplex virus-specified deoxypyrimidine kinase activity | Q45817992 | ||
| Relationship between viral neurotropism and oncolysis. II. Study of influenza virus | Q45824552 | ||
| Relationship between viral neurotropism and oncolysis. I. Study of vaccinia virus | Q45824556 | ||
| Modification of tumor cells by a low dose of Newcastle disease virus. Augmentation of the tumor-specific T cell response in the absence of an anti-viral response | Q45839247 | ||
| Experimental Therapy of Human Glioma by Means of a Genetically Engineered Virus Mutant | Q45854779 | ||
| Newcastle disease virus selectively kills human tumor cells | Q45865340 | ||
| Active specific immunotherapy with Newcastle-disease-virus-modified autologous tumor cells following resection of liver metastases in colorectal cancer. First evaluation of clinical response of a phase II-trial | Q45872022 | ||
| An adenovirus vector for gene transfer into neurons and glia in the brain | Q45874317 | ||
| A ten-year follow-up on stage II malignant melanoma patients treated postsurgically with Newcastle disease virus oncolysate | Q45875393 | ||
| Efficacy of p53 adenovirus-mediated gene therapy against human breast cancer xenografts. | Q45881106 | ||
| ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents | Q46343726 | ||
| Vaccinia colon oncolysate immunotherapy for murine hepatic metastases can be modulated with low-dose interleukin-2. Third place winner: Conrad Jobst Award | Q48407588 | ||
| Regression of Burkitt's lymphoma in association with measles infection. | Q53987611 | ||
| Attenuated veterinary virus vaccine for the treatment of cancer. | Q54055131 | ||
| [Prolonged spontaneous remission of chronic lymphoid leukemia] | Q54252296 | ||
| T-cell functions in ovarian cancer patients treated with viral oncolysates: I. Increased helper activity to immunoglobulins production. | Q54394704 | ||
| Infections in 18,000 infants and children in a controlled study of respiratory tract disease. I. Adenovirus pathogenicity in relation to serologic type and illness syndrome | Q64383775 | ||
| Remission of chronic lymphocytic leukemia after smallpox vaccination | Q67350064 | ||
| Adjuvant Immunotherapy with BCG in Treatment of Regional-Lymph-Node Metastases from Malignant Melanoma | Q67431779 | ||
| Active immunotherapy of human melanoma exploiting the immunopotentiating effects of cyclophosphamide | Q67927022 | ||
| Treatment of murine hepatic metastases with vaccinia colon oncolysates and IL-2 | Q68099227 | ||
| Superinfection of tumors with viruses | Q68598001 | ||
| [Vaccine therapy of malignant tumors] | Q68614258 | ||
| Positive relationship of clinical and serologic responses to vaccinia melanoma oncolysate | Q69463580 | ||
| Studies on the use of mumps virus for treatment of human cancer | Q34719177 | ||
| Active specific immunotherapy with vaccinia melanoma oncolysate | Q35229055 | ||
| Adenoviruses in the immunocompromised host | Q35231548 | ||
| Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy | Q35232341 | ||
| The pathogenicity of thymidine kinase-deficient mutants of herpes simplex virus in mice | Q36250741 | ||
| Active Specific Adjuvant Immunotherapy with Vaccinia Melanoma Oncolysate | Q36372868 | ||
| Transformation-dependent expression of interleukin genes delivered by a recombinant parvovirus | Q36697316 | ||
| Herpes simplex virus-mediated human hypoxanthine-guanine phosphoribosyltransferase gene transfer into neuronal cells | Q36781450 | ||
| Cellular promoters incorporated into the adenovirus genome: cell specificity of albumin and immunoglobulin expression | Q36899070 | ||
| Virus entry into animal cells | Q38226881 | ||
| Oncogenes-antioncogenes and virus therapy of cancer | Q38308126 | ||
| Down-regulation of the antitumor immune response. | Q39477532 | ||
| A new approach in specific, active immunotherapy | Q40047653 | ||
| Viral oncolysate in the management of malignant melanoma.I. Preparation of the oncolysate and measurement of immunologic responses | Q40089626 | ||
| Replicating vectors for gene therapy of cancer: risks, limitations and prospects | Q40470684 | ||
| Phase I study of a recombinant adenovirus-mediated gene transfer in lung cancer patients | Q40659851 | ||
| New developments in the virus therapy of cancer: a historical review | Q40745867 | ||
| Viral oncolysates in patients with advanced ovarian cancer | Q40787940 | ||
| Bispecific antibodies increase T-cell stimulatory capacity in vitro of human autologous virus-modified tumor vaccine. | Q41044825 | ||
| Parenteral gene therapy with p53 inhibits human breast tumors in vivo through a bystander mechanism without evidence of toxicity | Q41133661 | ||
| Chemical modification of an ecotropic murine leukemia virus results in redirection of its target cell specificity | Q41163805 | ||
| Treatment of Experimental Intracranial Murine Melanoma with a Neuroattenuated Herpes Simplex Virus 1 Mutant | Q41316787 | ||
| Immunogenicity increase of autologous tumor cell vaccines by virus infection and attachment of bispecific antibodies | Q41320994 | ||
| Controlling orthopoxvirus infections--200 years after Jenner's revolutionary immunization | Q41337646 | ||
| Systemic gene therapy with p53 reduces growth and metastases of a malignant human breast cancer in nude mice | Q41355839 | ||
| A Southeastern Cancer Study Group phase I/II trial with vaccinia melanoma oncolysates | Q41359422 | ||
| A preliminary trial of vaccinia oncolysates in the treatment of recurrent melanoma with serologic responses to the treatment. | Q41451037 | ||
| Stabilization of the p53 tumor suppressor is induced by adenovirus 5 E1A and accompanies apoptosis | Q41563751 | ||
| Simultaneous Administration of Live, Enteric-Coated Adenovirus Types 4,7, and 21 Vaccines: Safety and Immunogenicity | Q41689230 | ||
| Treatment of human cancer with mumps virus | Q42439769 | ||
| The complete DNA sequence of vaccinia virus | Q42634066 | ||
| Mechanisms of c-erbB2/neu oncogene-induced metastasis and repression of metastatic properties by adenovirus 5 E1A gene products | Q42815212 | ||
| Immunohistochemical studies on the interaction between Ehrlich ascites tumor cells and Newcastle disease virus | Q42822383 | ||
| Clinical studies of viruses as antineoplastic agents with particular reference to Egypt 101 virus | Q42977068 | ||
| A defective HSV-1 vector expresses Escherichia coli beta-galactosidase in cultured peripheral neurons | Q43244050 | ||
| Newcastle disease virus as an antineoplastic agent: induction of tumor necrosis factor-alpha and augmentation of its cytotoxicity | Q43553977 | ||
| Studies on live mumps virus vaccine. 3. Evaluation of newly developed live mumps virus vaccine | Q43904690 | ||
| Prevention of syngeneic tumor growth in vaccinia virus-primed mice by immunization with vaccinia virus-modulated tumor cells | Q43909281 | ||
| Adenovirus-mediated transfer of the CFTR gene to lung of nonhuman primates: toxicity study | Q44202627 | ||
| Adenovirus-mediated transfer of the muscle glycogen phosphorylase gene into hepatocytes confers altered regulation of glycogen metabolism | Q44509062 | ||
| Latent herpes simplex virus in spinal ganglia of mice | Q44563203 | ||
| p53 and DNA polymerase alpha compete for binding to SV40 T antigen | Q44581576 | ||
| Treatment of stage II malignant melanoma patients with a Newcastle disease virus oncolysate. | Q44714341 | ||
| Cyclophosphamide and abrogation of tumor-induced suppressor T cell activity | Q44963979 | ||
| Inhibition of growth of five transplantable mouse tumors by the virus of Russian Far East encephalitis | Q45689498 | ||
| NEWCASTLE DISEASE VIRUS AS AN ANTINEOPLASTIC AGENT. | Q45713156 | ||
| Present status of oncolytic virus studies | Q45717443 | ||
| Studies on the biological characteristics of the Newcastle disease virus (NDV) adapted to the brain of newborne mice | Q45719315 | ||
| Multiplication of influenza virus in the Ehrlich ascites carcinoma. | Q45719707 | ||
| Propagation of Newcastle disease virus in Ehrlich ascites cells in vitro and in vivo. | Q45720550 | ||
| A new host-virus system. | Q45721644 | ||
| Treatment of human breast cancer in a brain metastatic model by G207, a replication-competent multimutated herpes simplex virus 1. | Q45753117 | ||
| P433 | issue | 4 | |
| P921 | main subject | oncolytic virus | Q1560099 |
| P304 | page(s) | 375-386 | |
| P577 | publication date | 1999-01-01 | |
| P1433 | published in | Investigational New Drugs | Q2312231 |
| P1476 | title | Oncolytic viruses. | |
| P478 | volume | 17 |
| Q28069615 | Developments in Intralesional Therapy for Metastatic Melanoma |
| Q79117427 | Gene therapy for lung cancer |
| Q38657642 | In situ vaccination: Cancer immunotherapy both personalized and off-the-shelf. |
| Q39292187 | Investigation of cytotoxicity of negative control peptides versus bioactive peptides on skin cancer and normal cells: a comparative study. |
| Q35852258 | Oncolytic viral therapies |
| Q35635226 | Oncolytic virotherapy synergism with signaling inhibitors: Rapamycin increases myxoma virus tropism for human tumor cells |
| Q39752565 | STAT3 ubiquitylation and degradation by mumps virus suppress cytokine and oncogene signaling |
| Q35043098 | Selectively replicating viral vectors |
| Q34325219 | Treatment of advanced non-small-cell lung cancer: a review of current randomized clinical trials and an examination of emerging therapies |
| Q42149771 | VP2 capsid domain of the H-1 parvovirus determines susceptibility of human cancer cells to H-1 viral infection. |
Search more.